Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Deloitte
Johnson and Johnson
Argus Health
Fuji
Citi
Healthtrust
Accenture
US Army
McKesson

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,349,840

« Back to Dashboard

Which drugs does patent 8,349,840 protect, and when does it expire?


Patent 8,349,840 protects REXULTI and is included in one NDA.

This patent has twenty-six patent family members in twenty-five countries.

Summary for Patent: 8,349,840

Title:Piperazine-substituted benzothiophenes for treatment of mental disorders
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001##
Inventor(s): Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:12/970,690
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-001Jul 10, 2015RXYesNo► Subscribe► SubscribeY ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-002Jul 10, 2015RXYesNo► Subscribe► SubscribeY ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-003Jul 10, 2015RXYesNo► Subscribe► SubscribeY ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-004Jul 10, 2015RXYesYes► Subscribe► SubscribeY ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-005Jul 10, 2015RXYesNo► Subscribe► SubscribeY ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Otsuka Pharm Co Ltd
REXULTI
brexpiprazole
TABLET;ORAL205422-006Jul 10, 2015RXYesNo► Subscribe► SubscribeY ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,349,840

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-116698Apr 14, 2005

Non-Orange Book Patents for Patent: 8,349,840

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,888,362Piperazine-substituted benzothiophenes for treatment of mental disorders► Subscribe
9,206,167Piperazine-substituted benzothiophenes for treatment of mental disorders► Subscribe
9,480,686Piperazine-substituted benzothiophenes for treatment of mental disorders► Subscribe
8,618,109Piperazine-substituted benzothiophenes for treatment of mental disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,349,840

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina053577► Subscribe
Austria496911► Subscribe
Australia2006237905► Subscribe
BrazilPI0609785► Subscribe
Canada2602247► Subscribe
China101155804► Subscribe
Cyprus1111206► Subscribe
Germany602006019838► Subscribe
Denmark1869025► Subscribe
European Patent Office1869025► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
McKesson
Cantor Fitzgerald
Moodys
Dow
Express Scripts
Mallinckrodt
AstraZeneca
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot